Stability Testing of Drug Products
|
|
- Jerome Stewart
- 6 years ago
- Views:
Transcription
1 Stability Testing of Drug Products Scientific Criteries, guidelines and officiel state requirements in Europe, Japan and USA Edited by Dr. Wolfgang Grimm, Dr. Karl Thomae GmbH, D-Biberach International APV Symposium on Stability Testing of Pharmaceutical Products, Munich, December 2-4, 1985 Organized by Dr. P. Fischer, CH-Bern Prof. Dr. H. Feltkamp, Bayer AG, D-Leverkusen Dr. W. Grimm, Dr. Karl Thomae GmbH, D-Biberach Prof. Dr. H. Sucker, Sandoz AG, CH-Basel with 104figuresand 8 tables runiversstatsbibl1othek HANNOVER, TECKNISCHE i INFORMATIONS3IBLIOTHEK VOOCs Wissenschaftliche Verlagsgesellschaft mbh Stuttgart 1987
2 Contents Address of the authors: 12 Introduction (W. Grimm) 13 I. Physico-chemical changes from a molecular-galenical view point (R. Huttenrauch) Introduction Solid and semi-solid dosage forms, solids in suspensions Liquid dosage forms Final remarks 39 II. Physicochemical Criteria for semi-solid dosage forms (S.S. Davis) Introduction The various types of semi-solid forms Suspensions Emulsions Suppositories Gels Ointments and creams Evaluation of physicochemical properties Crystalline properties Sedimentation and creaming Consistency Accelerated tests Predictive methods Protocols for the evaluation of physical stability Stability limits and conclusions 54 m. Physico-chemical Criteria for the stability and stability forcast of solid dosage forms (M. Baltezor) Introduction Sensory properties Hardness Retained moisture 59
3 Contents 5. Disintegration Dissolution Conclusions 63 IV. Changes in medicinal products and the consequences for their therapeutic application (A. Verain) Introduction Notation of stability Stability and production The formulation process Structural changes Reactivity Sensibility to humidity Production Polymorphism Reactivity Humidity Mechanical manipulation Medicinal accidents due to faulty fabrication techniques or instabilities Incidents independent of the chemical structure of the active molecule Incidents related to the active molecule Conclusions 76 V. Japanese Guideline for Stability Testing (T. Nagai) Introduction Cooperative investigation on the establishment of the method for stability test for pharmaceutical preparations General matters concerning the data of stability testing to be submitted when applying for approval to manufacture (or import) new drugs Standards for stability testing of new drugs (March 31, 1980) Accelerated test standards Additional Guideline concerning the standards for stability testing of new drugs (June 8, 1984) 83 VI. Proposed FDA Guideline for Stability Testing (R. C. Shultz) Introduction Drug substance Drug product Statistical evaluation of an expiration dating period 90
4 Contents Design consideration for longterm studies under ambient conditions Selection of the batches Number of batches Selection of samples Testing sequence General product information Specifications and test methodology information Study design and study conditions Stability data information Data analysis and conclusions 96 VII. State of the official regulations concerning stability testing of pharmaceutical products in the EEC (B. Huyghe) Official regulations concerning stability testing of Belgium General introduction What can be said about in raw materials What can be said in 1985 about medicinal products in pharmaceutical form Acceptability of accelerated testing Number of batches required to perform the stability tests Number of temperatures required in stability tests Desirability to require stability tests in a high humidity atmosphere and/or in the presence of sufficient light Conclusions 101 VIII. Requirements of the Licensing Authority of the Federal Republic of Germany concerning the Stability Testing of Drug Products, with special reference to Phytopharmaceuticals (F.W. Hefendehl) Stability Tests according to the draft of a Drug Testing Guideline, Section dealing with Quality General requirements of stability tests Number of batches to be tested Duration of testing Equivalence of tests that were carried out under other conditions Testing frequency Test parameters Stability specificity Stability overages Foreign documentation and responsibility of the Pharmaceutical Manufacturer 107
5 Contents 4. Stability tests of phytopharmaceuticals Definition Peculiarities of crude drugs and crude drug preparations Stability tests of crude drugs and crude drug preparations Single crude drugs and crude drug preparations with known active substances Single crude drugs or crude drug preparations, whose active substances are not known Crude drug mixtures or mixed crude drug preparations with known active substances Crude drug mixtures or mixtures of crude drug preparations with unknown active substances Quality assessment of the general characteristics of various dosage forms of Phytopharmaceuticals during stability tests Ill Special provision for the stability testing of Phytopharmaceuticals Ill Summary and outlook 112 IX. Stability testing of pharmaceutical products: Official state requirements in France, Analytical approach and schema for the study of stability (F. Pellerin) Introduction Stability - study schedule Setting up the study Investigation of the active principle Reactivity of the molecule General study procedures Pharmaceutical dosage form stability test Moisture Antioxidants Functional group analysis and prediction of stability Forced oxidation Interpretation of the results and conclusions Analytical aspects Technical aspects, Conclusions 129 X. Great Britain, the DHSS Medicines Devision Requirement (A.G. Stewart) Introduction The underlying philosophy The pharmaceutical assessors 132
6 Contents 9 4. The guidelines Discussion Some effects of instability The drug substance/active constituent The dosage form The headings on stability Batches examined Conditions and duration of storage testing Containers Analytical methods Parameters tested Results Proposed shelf life Storage conditions, user instructions and pharmaceutical precautions On-going stability testing Conclusions 139 XL Stability and Stability Testing of Medicinal Products APV Guideline and Commentary APV Guideline Application and purpose Definition of stability Content of active ingredient Purity, degradation products Organoleptic, physico-chemical and microbiological characteristics Stability overage Storage time, shelf life Storage conditions Normal storage conditions Defined storage conditions Labelling Packaging Stability Testing Container and closure Accelerated studies Long term studies Storage conditions for long term studies Duration of studies Testing intervals Test criteria Test methods 144
7 10 Contents On-going stability Commentary on the APV Guideline (W. Grimm) Stability and stability testing of medicinal products Definition of stability Active ingredient Purity, degradation products Organoleptic, physico-chemical and microbiological characteristics Stability overage Stability period, shelf life Storage conditions Packaging Stability testing Accelerated stability tests Long term studies On-going Studies 150 XII. APV Guideline: Stability and Stability testing. State of the art in the field of stability and stability testing (W. Oeser) 151 Xm. Stability Testing in Industry (W. Grimm) Introduction Content of stability tests Description of the individual phases in a stability testing programme Tests with the drug substance Screening during pharmaceutical development Accelerated studies with the chosen formulation Long term testing Follow-up studies Tests after alterations to routine production Critical assessment of stability test programmes Cooperation with the Authorities The future of stability testing 169 XIV. Analytical methods of Stability Testing for chemically defined substances (S. Ebel) Introduction High pressure liquid chromatography Thin layer chromatography UV-spectrometry Voltammetry Titration procedures Conclusions 184
8 Contents 11 XV. Analytical procedures for stability testing of phytopharmaka and pharmaceutical products derived from natural compounds (G. Harnischfeger) Introduction General requirements Procedure for the planning of a stability test Predictable chemical change Redox reactions Interconversions Hydrolysis Condensations and polymerisations Isomerisations Photochemical processes Predictable galenical changes Technical limitations in stability testing of phytopharmaka Methods and their limitations Combination products Examples Final remarks :. 208 XVI. Stability Testing during development (K. Krummen) Introduction Drug substance reactivities Excipient compatibility Formulation comparison Stability of proposed product Conclusions 226 XVII. Packaging materials and shelf life (D. Herrmann) Introduction, General remarks Permeation, Plastic bottles Lyophilisates/Freeze-drying stoppers Glass Light protection Elastomeres/Rubber materials Plastics/General categories Collapsible tubes/aluminium Conclusions summary 239
GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)
GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) DRAFT GUIDANCE This guidance document is for feedback purposes only Comments and suggestions regarding this draft document should be submitted within
More informationStability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages.
Stability Report Stability profile of BIWG 98 SE tablets 40 mg Number SR 2001-01-04-01 Date Page 00. 00. 0000 1 of 133 Responsible Company Successful Pharma KG Biberach This stability report comprises
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit - FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: DEVELOPMENT PHARMACEUTICS FOR VETERINARY
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS
Association of South East Asian Nations (ASEAN) ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationAppendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version)
Appendices! (Translation from Original Chinese Version) Product quality documents Technical guidelines Appendix I General tests for various dose forms of pcms The general tests for various dose forms of
More informationBalancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL
Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels
More informationBringing ideas to life. Full-service pharmaceutical, nutraceutical and cosmetic contract manufacturing
Bringing ideas to life Full-service pharmaceutical, nutraceutical and cosmetic contract manufacturing Bringing ideas to life We built our Swiss pharmaceutical company on one idea born over 70 years ago,
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationInternational Journal of Generic Drugs
Photostability STABILITY TESTING in New Drug Products evaluating photostability is foremost for new chemical entities only - not in generic drugs, provided the container-closure protection is the same
More informationGUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS
GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any
More informationTEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES
VICH GL39 (QUALITY) November 2005 For implementation at Step 7 TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES Recommended for
More informationCorso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche E25. Fabbricazione Industriale dei Medicinali 4 CFU Prof.
Sezione di Tecnologia e Legislazione Farmaceutiche Maria Edvige Sangalli Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche E25 Fabbricazione Industriale dei Medicinali 4 CFU Prof. Andrea
More informationVICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
More informationSTABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationSTABILITY TESTING OF NEW DRUG
VICH GL5 (STABILITY 3) May 1999 For implementation at Step 7 STABILITY TESTING ESTING: PHOTOSTABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS Recommended for Implementation at
More informationPreface... iii Contents...vii Contributors...xv. 1 Introduction to Hot-Melt Extrusion, Continuous Manufacturing: Scale-up via Hot-Melt Extrusion...
Contents Preface... iii Contents...vii Contributors...xv 1 Introduction to Hot-Melt Extrusion, Continuous Manufacturing: Scale-up via Hot-Melt Extrusion... 1 1 Background... 1 1.1 Introduction... 1 1.1.1
More informationPractical Guide to Hot-Melt Extrusion: Continuous Manufacturing and Scale-up
Practical Guide to Hot-Melt Extrusion: Continuous Manufacturing and Scale-up Editor: Mohammed Maniruzzaman (C(%SM1THERS R A P R A A Smithers Group Company Shawbury, Shrewsbury, Shropshire, SY4 4NR, United
More informationQuality is Our Promise.
Quality is Our Promise. Our goal at KRS Global Biotechnology is to provide the highest quality pharmaceutical preparations. We accomplish this with an unrivaled quality assurance and quality control program
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationDesign and Dosage Form. Dr. Deny Susanti
Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationStatistical Evaluation Of Stability Data
Reprinted from FDA s website by #219 GUIDANCE FOR INDUSTRY Statistical Evaluation Of Stability Data VICH GL51 DRAFT GUIDANCE This guidance document is being distributed for comment purposes only Submit
More informationRepublic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a
Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a March 15, 1989 ADMINISTRATIVE ORDER No. 67 s. 1989 SUBJECT: Revised Rules and Regulations on Registration of Pharmaceutical
More informationCharity Ogunsanya CEO, Pharmabiodevice Consulting LLC Copyright 2014 By Pharmabiodevice Consulting LLC
Charity Ogunsanya CEO, Pharmabiodevice Consulting LLC www.pharmabiodeviceconsultant.com 10:00 a.m. 10:15 a.m. Introduction to the Virtual Conference Introduction to the Stability Testing Program Why Perform
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationEVALUATION FOR STABILITY DATA
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION FOR STABILITY DATA Q1E Recommended for
More informationA GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More information1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country
1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country S no 1. Name of Applicant with address 2. Name of Drug 3. Therapeutic Class 4. Date of Approval Documents
More informationO RAL C. apsules HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT. VOLUME II - PART ONE Drug Development - Solid Oral Dosage Forms.
HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT O RAL C Immediate Release apsules VOLUME II - PART ONE Drug Development - Solid Oral Dosage Forms Handbook of Pharmaceutical Generic Development Series ORAL
More informationSTANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards
Page: 1 of 6 1.Purpose The purpose of this Standard Operating Procedure is to establish a standardized procedure of using United States Pharmacopoeia (USP) standards, detailing the procedure of qualification,
More informationto The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.
STATUTORY INSTRUMENTS SUPPLEMENT No. 8 28th March, 2014 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government.
More informationVALIDATION OF RAW MATERIALS
Seminar On VALIDATION OF RAW MATERIALS By S.Rajesh kumar M.Pharmacy I SEM Department of Industrial pharmacy University college of pharmaceutical sciences Kakatiya university CONTENTS INTRODUCTION TO VALIDATION
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More informationWHO GENERAL GUIDANCE ON VARIATIONS TO MULTISOURCE PHARMACEUTICAL PRODUCTS. (February 2014)
February 2014 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 World Health Organization 2014 All rights reserved.
More informationCONTENTS 1 INTRODUCTION The Regulatory Focus on Quality Risk Management Objectives of Risk Assessment and Risk Management: The Key Concepts Key Terms in Relation to Risk and Risk Assessment Structure of
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationPHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS
RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June
More informationPharmaceutical Formulation Development of Peptides and Proteins
Pharmaceutical Formulation Development of Peptides and Proteins Edited by SVEN FROKJAER AND LARS HOVGAARD O* $L List of figures,' page xi List of tables xiii Contributors xv Preface xvii 1 Peptide Synthesis
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationOral Drug Delivery of Live Biotherapeutics for First In Human Studies
Oral Drug Delivery of Live Biotherapeutics for First In Human Studies Presented by Mike Frodsham Pharmaceutical Development Manager About Quay Pharmaceuticals About Quay Pharmaceuticals Contract development
More informationPost-Approval Change Regulations in Japan
Post-Approval Change Regulations in Japan Pharmaceuticals and Medical Devices Agency Office of Cellular and Tissue-based Products Futaba Honda, Ph.D. Agenda Application Forms and attached documents for
More informationGDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS
GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS 4 th Annual Symposium on Development of Generics & 505(b)(2) Achieving Access to Complex Drug Products: Integrating Scientific and
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationVICH Topic GL26 BIOLOGICALS: TESTING OF RESIDUAL MOISTURE
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections CVMP/VICH/096/01-Final London, 30 April 2002 VICH Topic GL26 Step 7 BIOLOGICALS: TESTING OF RESIDUAL MOISTURE
More informationDISSOLUTION TESTING OF GELS, TOPICAL CREAMS & OINTMENTS
AGILENT TECHNOLOGIES PRACTICAL SOLUTIONS NEWSLETTER VOLUME 15 ISSUE 4 PAGE 1 Dissolution Testing of Gels, Topical Creams & Ointments PAGE 4 Dispelling a Myth: 6- versus 12-Position Dissolution Units PAGE
More informationS terile. Injections HANDBOOK OF PHARMACEUTICAL. VOLUME 20 - Part One Drug Development - Sterile Injections GENERIC DEVELOPMENT
HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT S terile Injections VOLUME 20 - Part One Drug Development - Sterile Injections GENERIC DEVELOPMENT Handbook of Pharmaceutical Generic Development Series Sterile
More informationAnalytical and formulation attributes
Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding
More informationSTIMULI TO THE REVISION PROCESS
Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationExtractables and leachables: An Introduction
Extractables and leachables: An Introduction Tim Hulme Smithers Rapra THulme@smithers.com 44(0)1939 252 418 1 Extractables and leachables: An Introduction Tim Hulme Smithers Rapra thulme@smithers.com 2
More informationGUIDELINES ON STABILITY TESTING OF COSMETIC PRODUCTS. All rights reserved to CTFA and Colipa
GUIDELINES ON STABILITY TESTING OF COSMETIC PRODUCTS All rights reserved to CTFA and Colipa March 2004 GUIDELINES ON STABILITY TESTING OF COSMETIC PRODUCTS March 2004 I. GENERAL CONSIDERATIONS 1. INTRODUCTION
More informationInvestigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Overview 1. Requirements of the commercial stability program 2. Out of Specification
More information9 th PART. Registration of Active Pharmaceutical Ingredients
9 th PART Registration of Active Pharmaceutical Ingredients ANVISA Normative Instruction n. 15 and Resolution RDC n. 57, of November 17th, 2009 277 NORMATIVE INSTRUCTION N.15, OF NOVEMBER 17TH, 2009 The
More informationOutline. Opportunities Overview of ASAP Areas of Application ASAP Proposal to Regulators Summary
Outline Opportunities Overview of ASAP Areas of Application ASAP Proposal to Regulators Summary Opportunities n Provide cost benefits and possible alternate methods for demonstrating product stability
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationConsiderations for Ophthalmic Drug Products in Semi-Permeable Packaging
Considerations for Ophthalmic Drug Products in Semi-Permeable Packaging Bausch + Lomb Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products (PODP) February 22-23, 2011 Bethesda 23/02/2011
More informationEuropean Union, Trade in goods with South Korea
European Union, Trade in goods with South Korea Table of Contents pg - Key Figures 2 - / 2016 2 - - AMA/NAMA product Groups 2 - - SITC product Groups 2 - - Top 5 - HS sections 2 - - Top 5 - SITC sections
More informationEuropean Union, Trade in goods with Thailand
European Union, Trade in goods with Thailand Table of Contents pg - Key Figures 2 - / 2016 2 - - AMA/NAMA product Groups 2 - - SITC product Groups 2 - - Top 5 - HS sections 2 - - Top 5 - SITC sections
More informationPublic Assessment Report Scientific discussion. Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC
Public Assessment Report Scientific discussion Celecoxib Pfizer (celecoxib) SE/H/1076/01-02/DC This module reflects the scientific discussion for the approval of Celecoxib Pfizer. The procedure was finalised
More informationYour partner in the pharmaceutical industry
English Micronisation- and milling service Micronised by GfM Your API Particle size (µm) Your partner in the pharmaceutical industry The... always that little bit finer. We are a family business in the
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationBEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development
- ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,
More informationEuropean Union, Trade in goods with Uganda
European Union, Trade in goods with Uganda Table of Contents pg - Key Figures 2 - / 2017 2 - - AMA/NAMA product Groups 2 - - SITC product Groups 2 - - Top 5 - HS sections 2 - - Top 5 - SITC sections 2
More informationEvaluation of rice husk as an excipient for the pharmaceutical industry
Evaluation of rice husk as an excipient for the pharmaceutical industry Fernández_Ledesma E. 1, Rodríguez _Acosta C. 1, Liva_Garrido M. 2, Díaz_ Polanco I. 3, Cazanave_Guarnaluce D. 3 1 Engineering and
More informationPublic Assessment Report. Scientific discussion. Naproxennatrium Banner 220 mg capsules, soft (naproxen sodium) NL/H/2804/001/DC. Date: 28 April 2014
Public Assessment Report Scientific discussion Naproxennatrium Banner 220 mg capsules, soft (naproxen sodium) NL/H/2804/001/DC Date: 28 April 2014 This module reflects the scientific discussion for the
More informationProduct Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex
Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Brand Name : BOTO GENIE 1. Introduction : BOTO GENIE (Botulinum Toxin Type A for Injection Ph.Eur)
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationFormulation Development
Quality by Design and Formulation Development WF Busch Senior Application Development Specialist Dow Chemical Company IPEC Americas, Quality by Design Committee 5 May 2010 Disclaimer The views and opinions
More informationThis article specifically covers incorporation of physical and chemical indicators (PCIDs) into or onto the drug product.
Introduction The pharmaceutical industry is criminalized with circulation of counterfeit drugs risking healthcare and the life of users. This has become quite menacing in recent times with the lure of
More informationReference Standards for Monoclonal Antibodies: Key Challenges Addressed
CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges
More informationAbstract Process Economics Program Report 194A SUPERABSORBENT POLYMERS (April 2002)
Abstract Process Economics Program Report 194A SUPERABSORBENT POLYMERS (April 2002) Superabsorbent polymers (SAPs) represent a class of organic chemicals defined primarily by the their functional capability
More informationThe IPEC Excipient Stability Program Guide
The IPEC Excipient Stability Program Guide 2010 This document represents voluntary guidance for the pharmaceutical excipient industry and the contents should not be interpreted as regulatory requirements.
More informationQbD (Quality by Design) Has industry benefited from this? WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting There are many facets to engineering for a healthier world. It is important to understand what surrounds us today and look into what we believe will surround us
More informationChlorhexidine for Umbilical Cord Care
Chlorhexidine for Umbilical Cord Care Ensuring Supply of a Quality Product The Regional Dissemination Meeting Nepalgunj September 15-16, 2011 Outline of Presentation Selection of dosage forms Stability
More informationFormulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza
Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationEuropean Union, Trade in goods with MEDA (excluding EU) - (Mediterranean Countries In The Euro-Mediterranean Partnership)
European Union, Trade in goods with MEDA (excluding EU) - (Mediterranean Countries In The Euro- MEDA (excluding EU) - (Mediterranean Countries In The Euro- Albania, Algeria, Bosnia-Herzegovina, Egypt,
More informationEssentials in Stability Analysis and Expiry Determination
Published in BioPharma International. Essentials in Stability Analysis and Expiry Determination Thomas A. Little Ph.D. 6/12/2013 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland,
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationEuropean Union, Trade in goods with ACP -- West Africa
European Union, Trade in goods with ACP -- West Africa ACP -- West Africa Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria,
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationIs your next regulatory deadline within REACH?
Is your next regulatory deadline within REAC? 2018 500ml Smithers Viscient testing schedule REAC Annex VII/VIII Guideline Study Type Week Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
More informationASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT
ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT Update revision : 22 February 2005. 9 th ACCSQ-PPWG Meeting, Philippines, 21-24 Feb 2005 LIST OF CONTENTS 1. INTRODUCTION 1 2. OBJECTIVES 1 3. SCOPES
More informationPublic Assessment Report. Scientific discussion. Kruidvat Paracetamol liquid caps 500 mg, soft capsules. (paracetamol) NL License RVG:
Public Assessment Report Scientific discussion Kruidvat Paracetamol liquid caps 500 mg, soft capsules (paracetamol) NL License RVG: 116359 Date: 10 April 2017 This module reflects the scientific discussion
More informationO RAL. Tablets HANDBOOK OF PHARMACEUTICAL VOLUME I - Part ONE. Immediate Release GENERIC DEVELOPMENT
HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT O RAL Immediate Release Tablets VOLUME I - Part ONE Drug Development - Solid Oral Dosage Forms GENERIC DEVELOPMENT Handbook of Pharmaceutical Generic Development
More informationMASTER FILE PROCEDURES
MASTER FILE PROCEDURES Natural Health Products Directorate August 2006 Version 1.0 Our mission is to help the people of Canada maintain and improve their health, while respecting individual choices and
More informationExcipient Albumin CSL Behring Human Serum Albumin
Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse
More information